PODESTA GROUP, INC. for AMGEN
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Trade (domestic/foreign) TRD
International trade issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| PAUL BRATHWAITE | — |
| ANTHONY PODESTA | — |
Economics/Economic Development ECN
Economic policy.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ISRAEL S KLEIN | — |
| ANTHONY PODESTA | — |
Health Issues HCR
Prescription Drug User Fee Act reauthorization. Biosimilar products. H.R. 5651, Food and Drug Administration Reform Act of 2012. S. 3187, Food and Drug Administration Safety and Innovation Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SHARON COHEN | — |
Medicare/Medicaid MMM
Medicare Part B reimbursement and coverage of dialysis products.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SHARON COHEN | — |
Budget/Appropriations BUD
Prescription Drug User Fee Act reauthorization. H.R. 5651, Food and Drug Administration Reform Act of 2012. S. 3187, Food and Drug Administration Safety and Innovation Act. H.R. 5973/S. 2375, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2013.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SHARON COHEN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.